Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as Ozempic.

It used to be that Chinese drug development was largely about creating "me too" drugs for the local market. But over the past ...

Eli Lilly (NYSE ... although it was approved only in late 2023. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound ... telehealth company improperly referenced Lilly's approved drugs and clinical trials on its website in order to ...

The market for weight-loss drugs could see new entrants among existing biotech firms, with several drug candidates likely to be approved for ... particularly in China and Japan, where penetration ...

Eli Lilly, the drugmaker behind the blockbuster weight loss ... available drug. Mochi representatives did not respond to requests for comment. Lilly's complaint against Henry Meds alleges the ...